Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radiation technique aims to fight brain metastases while protecting memory

NCT ID NCT06518057

First seen Jan 08, 2026 · Last updated Jun 21, 2026 · Updated 29 times

Summary

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if this approach can control the cancer longer than standard radiation while causing fewer thinking and memory side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

craniospinal irradiation with hippocampal avoidance (proton therapy or VMAT)

What this could lead to

If it works, this could offer a way to control cancer spread in the brain and spine while reducing memory and thinking problems from radiation.

What could go wrong

This is a small, early-phase trial with only 22 participants, so results may not apply widely. The treatment may still cause side effects or fail to improve survival.

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm lung neoplasm Meningeal Carcinomatosis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.